Vir Biotechnology, Inc. VIR Change in estimated fair value of contingent consideration
Change in estimated fair value of contingent consideration at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:ChangeInEstimatedFairValueOfContingentConsideration.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s change in estimated fair value of contingent consideration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s change in estimated fair value of contingent consideration?
- Vir Biotechnology, Inc. (VIR) reported change in estimated fair value of contingent consideration of -$890K in Q1 2026.
- How has Vir Biotechnology, Inc.'s change in estimated fair value of contingent consideration changed year-over-year?
- Vir Biotechnology, Inc.'s change in estimated fair value of contingent consideration decreased by 186.4% year-over-year, from $1.03M to -$890K.
- What is the long-term trend for Vir Biotechnology, Inc.'s change in estimated fair value of contingent consideration?
- Over 2 years (2023 to 2025), Vir Biotechnology, Inc.'s change in estimated fair value of contingent consideration has grown at a 236.1% compound annual growth rate (CAGR), from $1.02M to $11.57M.
- What does change in estimated fair value of contingent consideration mean?
- This represents the non-cash adjustment to the liability for contingent consideration, such as earn-outs related to business acquisitions, based on changes in estimated future payouts. It reflects management's updated expectations regarding the likelihood of achieving performance milestones. A significant change indicates shifting outlooks on the success of acquired assets or technologies.